Wolfgang Halfbrodt

USPTO Granted Patents = 15 (Patent Applications = 1)

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 41(Granted Patents)

Company Filing History:

11 out of 1,384

Schering Aktiengesellschaft

patents

2 out of 12,164

Bayer Aktiengesellschaft

patents

1 out of 378

Bayer Pharma Aktiengesellschaft

patents

4. 1 out of 192

Bayer Schering Pharma Ag

patents

5. 1 out of 1

Schering Akitengesellschaft

patent

where one patent can have more than one assignee

Years Active: 1996-2025

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12303573 - Formulation of contrast media and process of preparation thereof (2025-05-20),

2. 11944690 - Formulation of contrast media and process of preparation thereof (2024-04-02),

3. 7683081 - 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2010-03-23),

4. 7345075 - 1,2 diarylbenzimidazoles and their pharmaceutical use (2008-03-18),

5. 7329679 - 1,2 Diarylbenzimidazoles and their pharmaceutical use (2008-02-12),

6. 7196202 - 1-aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2007-03-27),

7. 7115645 - 1,2 diarylbenzimidazoles and their pharmaceutical use (2006-10-03),

8. 6962932 - 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-11-08),

9. 6903126 - 1-Aryl-2-N-, S- or O-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-06-07),

10. 6855714 - 1-alkyl-2-aryl-benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives (2005-02-15),

11. 6147065 - 14-.alpha., 17-.alpha.-C.sub.2 bridged norprogesterone derivatives (2000-11-14),

12. 5973172 - 14-.alpha.,17-.alpha.-C.sub.2 -bridged norprogesterone derivatives (1999-10-26),

13. 5827842 - 14.alpha., 17.alpha.-C.sub.2 -bridged norprogesterone derivatives (1998-10-27),

14. 5703066 - Progestationally active 19,11-bridged 4-estrenes (1997-12-30),

15. 5523298 - Progestationally active 19,11-bridged 4-estrenes (1996-06-04),

Certainly! Here is an article about inventor Wolfgang Halfbrodt:

Title: Unveiling the Innovations of Wolfgang Halfbrodt: A Pioneer in Pharmaceutical Formulations

Introduction:

Wolfgang Halfbrodt, a distinguished inventor hailing from Berlin, Germany, has made significant strides in the field of pharmaceutical formulations. With a total of 14 patents to his name, Halfbrodt's groundbreaking contributions have revolutionized the healthcare industry.

Latest Patents:

Halfbrodt's recent patents showcase his prowess in developing cutting-edge pharmaceutical solutions. One of his notable inventions includes a liquid pharmaceutical formulation comprising a DOSA-derived tetra-chelate, ideal for imaging applications. Additionally, he has introduced 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives for the treatment of various diseases with immunological implications.

Career Highlights:

Having worked at esteemed companies such as Schering Aktiengesellschaft and Bayer Schering Pharma AG, Halfbrodt has honed his skills and expertise in pharmaceutical research and development. His diverse experience has shaped him into a trailblazer in the industry, with a keen focus on innovation and scientific advancement.

Collaborations:

Throughout his career, Halfbrodt has collaborated with industry peers like Joachim Kuhnke and Ursula Moenning. These collaborations have been instrumental in fostering a culture of innovation, driving forward-thinking research projects, and ultimately, bringing transformative solutions to the market.

Conclusion:

In conclusion, Wolfgang Halfbrodt's relentless dedication to innovation and scientific excellence has solidified his position as a visionary inventor in the realm of pharmaceutical formulations. His remarkable patents continue to push the boundaries of healthcare, offering new possibilities for diagnosis and treatment. Halfbrodt's legacy serves as an inspiration for aspiring inventors and underscores the profound impact of innovation in shaping a brighter future for healthcare worldwide.

This text is generated by artificial intelligence and may not be accurate.